Metabolic Solutions Development Company, LLC — Department of Health and Human Services SBIR Phase I: ? DESCRIPTION (provided by applicant): Polycystic kidney disease (PKD) is a term appli
Metabolic Solutions Development Company, LLC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $121,956
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA14-055
- NAICS
- —
- Place of performance
- MI
- Period
- —
Description
? DESCRIPTION (provided by applicant): Polycystic kidney disease (PKD) is a term applied to a group of inherited disorders characterized by the presence of cysts in the kidney although multiple organs are typically affected. Renal pathologies found inessentially all forms of PKD include increased fluid secretion, matrix remodeling, cellular proliferation, and apoptosis, with a altered differentiation of the epithelial cells lining the renal cysts. PKD represent conditions tht are inherited as either autosomal dominant (AD) or autosomal recessive traits. ADPKD occurs in 1-in-500 to 1-in-1000 individuals, primarily as a result of mutations in one of two genes, PKD1 or PKD2. These mutations drive a pathology which results in inactivation of AMPK and over-activation of mTOR and Wnt signaling pathways leading to inappropriate cellular proliferation of the epithelial cells lining the tubules of the nephron. At this time, there is no therapeutic intervention approved for halting PKD progression. Metabolic Solut